Shilpa Medicare arm gets NoC to conduct clinical studies for its Biosimilar Aflibercept

Listed pharmaceutical entity Shilpa Medicare on Monday informed the exchanges that its subsidiary Shilpa Biologicals (SBPL) has received a NoC from RCGM, Dept of Biotechnology to approach the Drugs Controller General of India (DCGI) to conduct clinical studies for its Biosimilar Aflibercept.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xY51nfE
via IFTTT